Gladwin Das, MD

Associate Professor of Medicine
Director, Interventional-Cardiology Hybrid Programs

Dr. Das completed his general- and interventional-cardiology fellowships at the University of Minnesota, joined the faculty in 1994, and served as the medical director of interventional cardiology and cardiac catheterization from 2005-February 2010. As director of the cardiac catheterization laboratory, Dr. Das established a Level I STEMI program and initiated process improvements resulting in median door-to-balloon times of less than 60 minutes. In partnership with Dr. Ken Liao of the division of cardiothoracic surgery, he has pioneered a growing hybrid percutaneous coronary intervention/robotic-assisted coronary-artery bypass grafting program, which he now directs.

Dr. Das holds several U.S. and international patents for transcatheter cardiac devices. Most notably, he pioneered the development of self-centering septal occluders with the Das AngelWings® device in the 1990s, and continues to work on device development in this and other areas. His concept of “true” self-centering intracardiac septal occluders has revolutionized the field, and provides minimally-invasive options for hundreds of thousands of patients worldwide.

Dr. Das has a special interest in the early diagnosis of acute coronary syndromes (ACS), and established the University of Minnesota Medical Center-Fairview’s Chest-Pain Center for the rapid triage and management of ACS patients. Focused on interventional cardiology, his clinical practice encompasses patients with coronary-artery disease or structural heart disease, including a special emphasis on transcatheter repair of cardiac septal defects. He is a co-PI for the national BARI 2D study.

A keen educator, Dr. Das has mentored a large number of residents, general-cardiology fellows, and interventional-cardiology fellows over the past 15 years. He chairs the University of Minnesota’s annual Lillehei symposium, a cardiovascular-care conference for primary practitioners.

Professional Organizations

• American Heart Association, member
• Cardiology Society of India, member

Selected Publications

Bypass Angioplasty Revascularization Investigation 2 Diabetes study group. Comparison of plasminogen activator inhibitor-1, tissue-type plasminogen activator antigen, fibrinogen, and D-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary-artery disease (from the BARI 2D trial). Am J Cardiol 2010;105:17-24

Bypass Angioplasty Revascularization Investigation 2 Diabetes study group. Association between albuminuria and duration of diabetes and myocardial dysfunction and peripheral arterial disease among patients with stable coronary-artery disease in the BARI 2D study. Mayo Clin Proc 2010;85:41-46

Bypass Angioplasty Revascularization Investigation 2 Diabetes study group. Relationships of obesity and fat distribution with atherothrombotic risk factors: Baseline results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Obesity 2009 (e-pub ahead of print)

Bypass Angioplasty Revascularization Investigation 2 Diabetes study group. Factors related to the selection of surgical vs. percutaneous revascularization in diabetic patients with multivessel coronary-artery disease in the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) trial. JACC Cardiovasc Interv 2009;2:384-392

Bypass Angioplasty Revascularization Investigation 2 Diabetes study group. Prevalence of diabetic peripheral neuropathy and relation to glycemic-control therapies at baseline in the BARI 2D cohort. J Peripher Nerv Syst 2009;14:1-13

Bypass Angioplasty Revascularization Investigation 2 Diabetes study group. Control of lipids at baseline in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Prev Cardiol 2009;12:9-18

Bypass Angioplasty Revascularization Investigation 2 Diabetes study group. Relation of severe coronary-artery narrowings to insulin or thiazolidideone use in patients with type 2 diabetes mellitus (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes study). Am J Cardiol 2009;1:104:52-58

Bypass Angioplasty Revascularization Investigation 2 Diabetes study group. Baseline coronary angiographic findings in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial (BARI 2D). Am J Cardiol 2009;1:103:632-638

Bypass Angioplasty Revascularization Investigation 2 Diabetes study group. Baseline characteristics of patients with diabetes and coronary-artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Am Heart J 2008;156:528-536,536.e1-5

Manuscripts in Preparation

Bates E, Das G, Lopez J, Misra VJ, Nedeljkovic Z, Neuzil P, Satervino L, Srinivas VS for the BARI 2D study group. "Comparison of the results of revascularization of bare-metal stents compared to drug-eluting stents in the BARI 2D trial."

Sonbol Y, Raveendran G, Wilson RF, Das GS. "Transcatheter closure of interatrial septal defects in adult patients with right-to-left shunts."

Liao K, Iyer VS, Berger A, Raveendran G, Yannopoulos D, Wilson RF, Das GS. "Hybrid and robotic-assisted coronary revascularization: Initial experience at the University of Minnesota."